A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer

Cancer Genomics and Proteomics

Volumn 6, Issue 2, 2009, Pages 93-100

  Sooriakumaran, P ^a,b   Macanas Pirard, P ^a   Bucca, G ^a   Henderson, A ^a,b   Langley, S E M ^a,b   Laing, R W ^b   Smith, C P ^a   Laing, E E ^a   Coley, H M ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Celecoxib; COX 2 inhibition; Gene expression; Neo adjuvant; Prostate cancer

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C; ALPHA TUBULIN; BETA7 INTEGRIN; CELECOXIB; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN B1; CYTOKERATIN 18; GLUCOSE REGULATED PROTEIN 94; HEPATOMA DERIVED GROWTH FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; MYOSIN LIGHT CHAIN KINASE; NUCLEOSIDE DIPHOSPHATE KINASE NM23; PROTEIN P73; RIBOSOMAL PROTEIN L1; RIBOSOMAL PROTEIN L13A; RIBOSOME PROTEIN; RIBOSOME PROTEIN S9; SARCOGLYCAN; SERINE PROTEINASE INHIBITOR; SIGNAL RECOGNITION PARTICLE; SOMATOMEDIN B RECEPTOR; SURVIVIN; TRANSCRIPTION FACTOR NRF2; TRANSGELIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFICACY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SINGLE BLIND PROCEDURE; TUMOR LOCALIZATION;

EID: 65749113139     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 54: 8-29, 2004.
2. Sooriakumaran P, Langley SEM, Laing R and Coley HM: Review:- COX-2 inhibition - a possible role in the management of prostate cancer? J Chemother 19: 21-32, 2007.
3. Cohen BL, Gomez P, Omori Y, Duncan RC, Civantos F, Soloway MS, Lokeshwar VB and Lokeshwar BL: Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 119: 1082-1087, 2006.
4. Khor LY: COX-2 expression predicts prostate - cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 8: 912-920, 2007.
5. Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A, Eden CG, Miller PD, Langley SEM and Laing RW: A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res: in press, 2009.
6. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ and Coltman CA Jr: The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3): 215-224, 2003.
7. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5: R80, 2004.
8. Smyth GK and Speed TP: Normalization of cDNA microarray data. Methods 31: 265-273, 2003.
9. Breitling R, Armengaud P, Amtmann A and Herzyk P: Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Letters 573: 83-92, 2004.
10. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL and Chory J: RankProd: A Bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22: 2825-2827, 2006.
11. Mehar A, Macanas-Pirard P, Mizokami A, Takahashi Y, Kass GEN and Coley HM: The role of COX-2 in apoptotic response to cytotoxic agents in prostate cancer cells. J Pharmacol Experiment Therapeut 324: 1-7, 2008.
12. Gomez LA, de las Pozas A, Reiner T, Burnstein K and Perez-Stable C: Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy. Mol Cancer Ther 6: 1534-1543, 2007.
13. Utz PJ, Hottelet M, Le TM, Kim SJ, Geiger ME, van Venrooij WJ and Anderson P: The 72kDa component of signal recognition particle is cleaved during apoptosis. J Biol Chem 273: 35362-35370, 1998.
14. Ren Y-G, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M and Deveraux QL: Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell 15: 5064-5074, 2004.
15. Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, Xu J, Goldberg ID, Jaiswal AK and Rosen EM: BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 64: 7893-7909, 2004.
16. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA and Offit K: BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10: 2918-2921, 2004.
17. Muller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH and Schilling T: One, two, three - p53, p63, p73 and chemosensitivity. Drug Resistance Updates 9: 288-306, 2006.
18. Beitzinger M, Hoffman L, Oswald C, Beinoraviciute-Kellner, Sauer M, Griesmann H, Bretz AC, Burek C, Rosenwald A and Stiewe T: P73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J 27: 792-803, 2008.
19. Gu L-Z, Hu W-Y, Antic N, Mehta R, Turner JR and de Lanerolle P: Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells. Eur J Cancer 42: 948-957, 2006.
20. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, Gao GJ and Reed JC: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9: 4919-4925, 2003.
21. Krysan K, Merchant Fh, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Pold M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R and Sharma S: COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 18:206-208 B, 2004.
22. Yoo J and Lee YJ: Aspirin enhances tumor necrosis factor related apoptosis inducing ligand-mediated apoptosis in hormone refractory prostate cancer cells through survivin down-regulation. Mol Pharmacol 72: 1586-1592, 2007.
23. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Sridar, Barnes AS, Trempany C, Catalona W, Kantoff PW and Oh WK: Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11: 5233-5240, 2005.
24. Pruthi RS, Derksen JE and Moore D: Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 12: 2172-2177, 2006.